BOCA RATON, Fla.--(BUSINESS WIRE)--Sep. 25, 2017--
TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the pricing
of an underwritten public offering of 12.4 million shares of its common
stock at a price to the public of $5.65 per share. All of the shares in
the offering are to be sold by TherapeuticsMD. The offering is expected
to close on or about September 28, 2017, subject to the satisfaction of
customary closing conditions.
J.P. Morgan is acting as sole book-running manager for the offering.
TherapeuticsMD intends to use a majority of the net proceeds from the
offering to fund pre-commercialization and commercialization activities
for TX-004HR, the Company’s applicator-free vaginal estradiol softgel
drug candidate for the treatment of moderate-to-severe vaginal pain
during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal
atrophy (VVA) due to menopause, and TX-001HR, the Company’s
bio-identical hormone therapy combination of 17ß- estradiol and
progesterone in a single, oral softgel drug candidate for the treatment
of moderate to severe vasomotor symptoms (VMS) due to menopause in
post-menopausal women with an intact uterus, for other research,
clinical trials, clinical formulation and development and for working
capital and general corporate purposes.
TherapeuticsMD has filed a shelf registration statement on Form S-3,
including a prospectus supplement and accompanying prospectus, with the
Securities and Exchange Commission (the “SEC”), relating to the public
offering of the shares of common stock described above. Before buying
any shares of TherapeuticsMD’s common stock in the offering, you should
carefully read the prospectus supplement and the accompanying
prospectus, together with the information incorporated therein. These
documents contain important information that you should consider when
making your investment decision. TherapeuticsMD’s SEC filings are
available to the public from the SEC’s website at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to these securities may also be obtained by contacting J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewater, NY 11717, or telephone: 866-803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s late stage clinical pipeline includes two phase 3 product
candidates: TX-001HR for treatment of moderate-to-severe vasomotor
symptoms (VMS) due to menopause and TX-004HR for treatment of
moderate-to-severe vaginal pain during sexual intercourse (dyspareunia),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The
company also manufactures and distributes branded and generic
prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD®
brands.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: risks and uncertainties associated with market
conditions, the satisfaction of customary closing conditions related to
the offering; the company’s ability to resolve the deficiencies
identified by the FDA in the company’s new drug application for its
TX-004HR product candidate and the time frame associated with such
resolution; whether the company will be able to prepare an amended NDA
for its TX-004HR product candidate and, if prepared, whether the FDA
will accept and approve the NDA; the company’s ability to maintain or
increase sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; whether the company will be able to
prepare an NDA for its TX-001HR product candidate and, if prepared,
whether the FDA will accept and approve the NDA; the length, cost and
uncertain results of the company’s clinical trials, including any
additional clinical trials that the FDA may require in connection with
TX-004HR; the potential of adverse side effects or other safety risks
that could preclude the approval of the company’s hormone therapy drug
candidates; the company’s reliance on third parties to conduct its
clinical trials, research and development and manufacturing; the
availability of reimbursement from government authorities and health
insurance companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company’s common
stock and the concentration of power in its stock ownership; and
the transfer of the company’s stock listing from the NYSE American to
the Nasdaq Global Select Market. PDF copies of the company’s historical
press releases and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006566/en/
Source: TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
David DeLucia, 561-961-1900
Director,
Investor Relations
David.DeLucia@TherapeuticsMD.com